Reata Pharmaceuticals Valuation
| RETADelisted Stock | USD 109.67 3.31 2.93% |
At this time, the company appears to be overvalued. Reata Pharmaceuticals holds a recent Real Value of $87.46 per share. The prevailing price of the company is $109.67. Our model determines the value of Reata Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of -1.12, current valuation of 6.4 B, and Shares Owned By Insiders of 4.10 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Reata Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Reata Pharmaceuticals is based on 3 months time horizon. Increasing Reata Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Reata Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reata Stock. However, Reata Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 109.67 | Real 87.46 | Hype 109.67 | Naive 113.45 |
The real value of Reata Stock, also known as its intrinsic value, is the underlying worth of Reata Pharmaceuticals Company, which is reflected in its stock price. It is based on Reata Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Reata Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Reata Pharmaceuticals helps investors to forecast how Reata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reata Pharmaceuticals more accurately as focusing exclusively on Reata Pharmaceuticals' fundamentals will not take into account other important factors: Reata Pharmaceuticals Total Value Analysis
Reata Pharmaceuticals is at this time anticipated to have valuation of 6.4 B with market capitalization of 6.57 B, debt of 119.46 M, and cash on hands of 481.47 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Reata Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
6.4 B | 6.57 B | 119.46 M | 481.47 M |
Reata Pharmaceuticals Investor Information
About 88.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.62. Reata Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Reata Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Reata Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Reata Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Reata Pharmaceuticals has an asset utilization ratio of 0.43 percent. This suggests that the Company is making $0.004307 for each dollar of assets. An increasing asset utilization means that Reata Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Reata Pharmaceuticals Ownership Allocation
Reata Pharmaceuticals owns a total of 33.59 Million outstanding shares. The majority of Reata Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Reata Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Reata Pharmaceuticals. Please pay attention to any change in the institutional holdings of Reata Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Reata Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 2.22 M. Net Loss for the year was (311.9 M) with loss before overhead, payroll, taxes, and interest of (167.63 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Reata Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Reata Pharmaceuticals and how it compares across the competition.
About Reata Pharmaceuticals Valuation
The delisted stock valuation mechanism determines Reata Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Reata Pharmaceuticals. We calculate exposure to Reata Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Reata Pharmaceuticals's related companies.Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas. Reata Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 346 people.
Reata Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 36.3 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Reata Stock
If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |